All News

Article

EMA Final Update on JAK Inhibitors and MACE, Malignancy & VTE Risks

Jack Cush, MD Apr 03, 2023

The EMA has updated recommendations regarding the use of JAK inhibitors by issuing a direct healthcare professional communication summarizing the data and warnings regarding an increased risk of malignancy, major adverse cardiovascular events (MACE), serious infections, VTE, and mortality in some patients receiving JAKi for the treatment of chronic inflammatory disorders.

Article

The Origin Story of RheumNow’s Campaign: Women in Rheumatology--The XX Factor

Kathryn H. Dao, M.D., , Rachel Tate, DO Apr 03, 2023

Origin stories have captivated me ever since my childhood spent reading Greek Mythology and Marvel comic books. Superheroes have different powers and personalities.

Atopic Disease Increases Osteoarthritis Risk Analysis of commercial insurance claims suggests that patients with asthma or atopic dermatitis have a significantly increased risk of osteoarthritis (OA). https://t.co/450DnhOfY5 https://t.co/zUfD4jhumY

https://bit.ly/3zpnhCy

Frunevetmab (Solensia), is a cat-specific mAb against nerve growth factor was FDA approved, for use in CATS, to treat the pain of osteoarthritis. CATS! https://t.co/vY0CCMjZmC https://t.co/UnpDpo5fyB

https://bit.ly/40w6pGp

Tomorrow! Join us for Tuesday Night Rheumatology. Our panelists will discuss the challenges they have faced trying to manage a career and family life, as well as provide advice and strategies for managing competing priorities and obligations. https://t.co/OlP0pupkMV https://t.co/pZQMASafcG

https://bit.ly/3M450lN

Abbvie has completed a phase II upadacitinib vs combo elsubrutinib/upadacitinib ( ABBV-599) in active #SLE - M19-130 (SLEek) Phase 2 trial met the primary endpoint SRI-4 response and pred dose<=10 mg qd. No new safety signals - Phase III trial planned https://t.co/6CwS2AVamH https://t.co/b4wQ6IoiOz

https://bit.ly/3nG1fJ5

Gender Gap in Editors. Cross-sect study of top 10 Intl medical journals in 41 categories shows women underrepresented as editors in chief. Women editors=21%. No women editors in dentistry, oral surgery; allergy, psychiatry; anesthesiology; ophthalmology https://t.co/JWAwrO9F4w https://t.co/0viEMa6ImK

https://bit.ly/3Uj8eEp

Variability in rheumatologist steroid prescribing - using data on ~500k RA pts and 6,875 rheumatologists. Those LESS likely to prescribe alot of steroids were: women, solo practitioners, in practice ≥10 years, seeing greater#s of RA pts/year https://t.co/ELk0avorOe

https://bit.ly/3U8T8B1

Open-label Trial of 14 pts with MAS due to steroid refractory systemic JIA or adult-onset Still’s demonstrated the efficacy of IV emapalumab, an anti-IFNγ mAb. Demonstrated signif reductions in LDH, sIL-2R, Ferritin, CXCL9, & steroid dose https://t.co/vgxT5KzmQF https://t.co/gDLmfOlSHG

https://bit.ly/3lV5RLb

Mom in Medicine BINGO - Just try to Win! #WIR https://t.co/Mb4KtsWQPK

https://bit.ly/3K8SX46

LAVLI - A New Autoinflammatory Disorder NIH researchers have have described a novel autoinflammatory disorder called "Lyn kinase-associated vasculopathy and liver fibrosis" (LAVLI), based on a mutation in the LYN gene. https://t.co/RYmb3QFB1T https://t.co/sn5hwVxwPk

https://bit.ly/3ZvUw1U

2022 EULAR Recommendations for ANCA-associated Vasculitis EULAR has published the 2022 update on recommendations for the management of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). https://t.co/lvPO26S0k6 https://t.co/cQtiEctrTR

https://bit.ly/3K4tSHL

30 consecutive seropositive (CCP or RF+) early RA pts - 60% had pulmonary abnormalities (PA). PA correlated with presence of neutrophil activation, parameters of inflammation and RF titres. https://t.co/dsbjPhuYzf https://t.co/1Zmyqjuaxj

https://bit.ly/3ZspPdH

Autoimmune-Rheum Dz (AIRD) flares occur in 10% w/ COVID vaccination, esp in pts w/ comorbidities, autoimmune morbidities & mental health disorders & Moderna vaccine. 3453 AIRD pts who recv Vax 9.5-11.3% had clinical flares (Arthritis 62% & fatigue 59%) https://t.co/C0WA2Znixl https://t.co/vXzL8XR7kd

https://bit.ly/3U1UcXt

Tofacitinib May Reduce Interstitial Lung Disease Risk in RA Tofacitinib (Xeljanz) in patients with RA stood out among several other biologic and targeted sDMARDs when it came to the incidence of ILD, a retrospective cohort study showed. https://t.co/2DCn53Rk4z https://t.co/sZYhgfCU0E

https://bit.ly/42TKNVU

Intrathecal Methotrexate for Cerebritis Dr. Jack Cush reviews the CV advantage to walking, the OA risk with running and the eczema-OA connection; these articles and journal reports from the past week on RheumNow. https://t.co/wTOehtaU27 https://t.co/8Xp0C6tqBe

https://bit.ly/3nDEMwr

Join RheumNow during the month of April as we discuss Women in Rheumatology, the XX Factor. Sign up to attend our series! https://t.co/e3AJKwnoWs https://t.co/cpUmsOVuAT

https://bit.ly/3K4apGU

Network metaanalysis of 7 dietary RCTs in high risk CV pts (40 RCTs, 35 548 pts), showed only Mediterranean (OR 0.72) & low fat (OR 0.84) diet reduce all cause mortality; Med-diet also reduced CV mortality (0.55), stroke (0.65) & non-fatal MI (0.48) https://t.co/ibUknLlwOx https://t.co/zRtvXObvg3

https://bit.ly/40NtS5t

RCT shows vitamin D does not improve psoriasis. 122 mild PSO pts (PASI=3.1) w/ mean low vit D levels 14.9 ng/mL; randomized to vit D (20KIU/wk) or placebo. At 4 mos, vit D levels rose to 30 w/ Rx, but no signif improvement in PASI change, MD global or DLQI https… https://t.co/OI5v1y5t0u

There are 27 US States where Nurse Practitioners have "Full Practice Authority" - including WA, OR, NV, ID, UT, MT, AZ, CO, WY, NM, ND, SD, NE, KS, Minn, NY, ME, VT, NH, MA, CT, RI, MD, DE, DC https://t.co/hA9Sd63bDW https://t.co/9MM6CTH4gX

https://bit.ly/42VA11y

Topics

All News

EMA Final Update on JAK Inhibitors and MACE, Malignancy & VTE Risks

The Origin Story of RheumNow’s Campaign: Women in Rheumatology--The XX Factor

Do you get our email newsletter?